JMT-601

N/A

Report date: 2025/04/22 16:24:53

Base Information

Drug NameJMT-601
Drug Alias NameJMT-601
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsAnti-CD20
TargetsCluster of differentiation 47B-lymphocyte antigen CD20
Therapy Area/IndicationsNephrosisGlomerulonephritis, MembranousLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Jmt-Bio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Jmt-Bio Inc
Inactive CompaniesN/A
Active IndicationsNephrosisGlomerulonephritis, MembranousLymphoma, Large B-Cell, Diffuse +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A